Research + Development

IMO-9200: An Oral Synthetic Oligonucleotide for the Treatment of GI Inflammation.

IMO-9200 is an orally delivered, synthetic oligonucleotide antagonist of toll-like receptors (TLRs) 7,8 and 9 with limited systemic bioavailability. TLRs are part of a normally functioning intestinal immune system and interface among intestinal epithelia, gut microbiota, and the immune system. Activation of TLR by gut bacterial DNA triggers inflammation. IMO-9200 activity has been demonstrated in pre-clinical models of acute and chronic GI tract inflammation, and safety demonstrated in a phase 1 clinical trial in healthy subjects (SC administration).

The estimated prevalence of immune-mediated inflammatory diseases in Western society is 5% - 7%, and commonly used immunosuppressant agents to manage these diseases may lead to devastating long-term side effects. IMO-9200 may offer a solution for GI inflammatory diseases with a better side effect profile than currently available drugs.

*Includes Worldwide Development and Commercial Rights.